Source:http://linkedlifedata.com/resource/pubmed/id/10940873
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2000-9-13
|
| pubmed:abstractText |
Seasonal allergic conjunctivitis is one of the most common manifestations of allergic disease, affecting 15 % population in the United States annually. Short ragweed (RW) is a major cause of seasonal allergies. Immunostimulatory DNA sequences (ISS or CpG motifs) can inhibit an on-going Th2/allergic response and induce a de novo Th1 response. In this study, we investigated the ability of these ISS to modulate allergic responses in a RW-induced mouse model of seasonal allergic conjunctivitis. Systemic or mucosal administration of ISS oligonucleotide (ISS-ODN) after RW sensitization inhibited both the immediate hypersensitivity response and the late-phase cellular infiltration and induced a RW-specific Th1 response. ISS-ODN administration suppressed the rise of RW-specific IgE titers after repeated allergen challenge. Furthermore, ISS administration was more effective than dexamethasone in inhibiting the allergic response. Mechanistically, the ISS-induced immunomodulatory effects were abolished when mice were treated with anti-IL-12 neutralizing antibodies, suggesting a pivotal role for type 1 cytokines in the inhibition of both the immediate hypersensitivity and the late-phase cellular infiltration. Thus, ISS-ODN is a novel anti-inflammatory and immunomodulatory agent that significantly inhibits the allergic response and may provide an alternative to the current standard care of ocular allergy.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0014-2980
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
30
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1841-50
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:10940873-Administration, Topical,
pubmed-meshheading:10940873-Allergens,
pubmed-meshheading:10940873-Animals,
pubmed-meshheading:10940873-Conjunctivitis, Allergic,
pubmed-meshheading:10940873-DNA,
pubmed-meshheading:10940873-Disease Models, Animal,
pubmed-meshheading:10940873-Down-Regulation,
pubmed-meshheading:10940873-Hypersensitivity, Delayed,
pubmed-meshheading:10940873-Hypersensitivity, Immediate,
pubmed-meshheading:10940873-Immunoglobulin E,
pubmed-meshheading:10940873-Injections, Intraperitoneal,
pubmed-meshheading:10940873-Mice,
pubmed-meshheading:10940873-Mucous Membrane,
pubmed-meshheading:10940873-Oligodeoxyribonucleotides,
pubmed-meshheading:10940873-Poaceae,
pubmed-meshheading:10940873-Pollen,
pubmed-meshheading:10940873-Th1 Cells,
pubmed-meshheading:10940873-Time Factors
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis.
|
| pubmed:affiliation |
National Eye Institute, National Institutes of Health, Bethesda 20892-1857, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|